CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its key “Alnylam 5x15” and partner program goals for 2012.
“Today, we are increasing our guidance to end 2011 with approximately $260 million in cash. We will provide financial guidance for 2012 in connection with our 2011 financial results announcement in February.” “The last 12 months represent a remarkable period of clinical accomplishments for Alnylam’s pipeline efforts where we demonstrated RNAi proof of mechanism in biopsy samples from our ALN-VSP liver cancer program, showed clear human proof of concept in patients with robust silencing of a disease gene in our ALN-TTR program, and documented first-ever clinical efficacy for RNAi therapeutics in our ALN-PCS program. Indeed, we believe these achievements greatly strengthen our ‘Alnylam 5x15’ product strategy, and we are more confident than ever in our ability to harness the RNAi pathway for the development of high impact, innovative medicines,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.
“Today, we are increasing our guidance to end 2011 with approximately $260 million in cash. We will provide financial guidance for 2012 in connection with our 2011 financial results announcement in February.” “The last 12 months represent a remarkable period of clinical accomplishments for Alnylam’s pipeline efforts where we demonstrated RNAi proof of mechanism in biopsy samples from our ALN-VSP liver cancer program, showed clear human proof of concept in patients with robust silencing of a disease gene in our ALN-TTR program, and documented first-ever clinical efficacy for RNAi therapeutics in our ALN-PCS program. Indeed, we believe these achievements greatly strengthen our ‘Alnylam 5x15’ product strategy, and we are more confident than ever in our ability to harness the RNAi pathway for the development of high impact, innovative medicines,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.
